Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant Melanoma

Update Il y a 4 ans
Reference: EUCTR2007-006713-16

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to determine the progression-free survival (PFS) of patients with metastatic malignant melanoma who have not received prior chemotherapy for metastatic disease when treated with IMC-1121B alone or in combination with dacarbazine.


Inclusion criteria

  • Metastatic Malignant Melanoma

Links